HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, March 29, 2019 (HealthDay News) -- A simple point-of-care urine test can rapidly detect preeclampsia, according to a study published in the February issue of EClinicalMedicine.
Kara M. Rood, M.D., from The Ohio State University College of Medicine in Columbus, and colleagues evaluated the diagnostic performance of a paper-based point-of-care test for detecting urine congophilia as a method for rapid triage and diagnosis of preeclampsia. In total, 346 consecutive pregnant women who were evaluated for preeclampsia in a single labor and delivery triage unit were included. The Congo Red Dot (CRD) Paper Test was compared to an expert-adjudicated diagnosis in each case and to urine and serum analytes (placental growth factor and soluble fms-like tyrosine kinase-1).
The researchers found that during the first triage visit, 32 percent of women received a clinical diagnosis of preeclampsia, although 63 percent were admitted for inpatient diagnostic work-up or delivery. The CRD Paper Test was positive in 25 percent of the 346 cases and preeclampsia was confirmed in 28 percent of all cases. The CRD Paper Test outperformed the serum and urine markers evaluated (80.2 percent sensitivity, 89.2 percent specificity, 92.1 percent negative predictive value, 86.7 percent accuracy). Thirty-eight percent of women who were discharged undelivered had at least one additional triage visit, with an interval of 12 days between the last negative and first positive CRD Paper Test.
"Implementation of the CRD Paper Test in the triage area could be a useful tool for rapid diagnosis of [preeclampsia] and avoidance of unnecessary deliveries," the authors write.
Two study authors are named as inventors or coinventors on patent applications filed by Yale University on the use of protein misfolding for diagnostic and treatment purposes of preeclampsia. They also received royalties from Yale.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 27, 2022